Class / Patent application number | Description | Number of patent applications / Date published |
546273100 | Polycyclo ring system having the 1,3-diazole ring as one of the cyclos | 88 |
20160176892 | BENZIMIDAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL COMPOSITIONS AND USES | 06-23-2016 |
546273400 | Bicyclo ring system which is benzimidazole (including hydrogenated) | 87 |
20080214827 | Synthesis of Cyanoimino-Benzoimidazoles - Disclosed in certain embodiments is a process for synthesizing a compound of formula (V) and salts thereof. | 09-04-2008 |
20080269497 | Hydrates of Optionally Substituted 2-(2-Pyridinyl) Methylthio-1H-Benzimidazoles and Process for the Production Thereof - The invention relates to crystals from optionally substituted 2-(2-pyridinyl)methylthio-1H-benzimidazole hydrates and to a method for the production thereof. | 10-30-2008 |
20080287682 | Substituted benzimidazoles and methods of preparation - Methods for preparing new substituted benzimidazole compounds having formula (I) useful for treating kinase mediated disorders are provided wherein R | 11-20-2008 |
20090036685 | Process for Producing Imidazothiazole Derivatives - Disclosed is a process for producing an imidazothiazole derivative of formula (I) useful as an intermediate for the production of carbapenem derivatives having potent antimicrobial activity and a broad antimicrobial spectrum, that is, a novel method for nicotinoylating an imidazo[5,1-b]thiazole ring at its 7-position. The process comprises reacting a compound of formula (II) with a compound of formula (III). | 02-05-2009 |
20100004458 | PROCESS FOR PRODUCING CRYSTAL - The present invention relates to a production method of a crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]benzimidazole.n′H | 01-07-2010 |
20100099882 | PROCESS FOR THE PREPARATION OF A BENZIMIDAZOLE DERIVATIVE - The invention relates to a process for preparing the compound of formula 1, a valuable intermediate product in the synthesis of the pharmaceutical active substance dabigatran etexilate. | 04-22-2010 |
20100121068 | Process for preparing rabeprazole sodium - The present invention provides a process for preparing the amorphous rabeprazole sodium. The process comprises the following steps: (a) Contacting rabeprazole sodium compound with a solvent system to thereby obtain a clear solution under a first temperature, wherein said solvent system is a mixture of at least two categories of organic solvents; (b) Stirring said clear solution of step (a) under a second temperature for a certain time period to obtain a solution containing resultant separated solid, wherein said second temperature is equal to or lower than said first temperature; (c) Filtering said solution containing resultant separated solid obtained from step (b) to obtain a wet solid; and (d) Drying said wet solid to obtain an amorphous rabeprazole sodium compound. | 05-13-2010 |
20100324298 | Novel Process for the Preparation of Esomeprazole and Salts Thereof - A novel process for the preparation of omeprazole and its enantiomers, such as esomeprazole, as well as the preparation of related 2-(2-pyridinylmethyl-sulphinyl)-1H-benzimidazoles, including pantoprazole, lansoprazole and rabeprazole, as recemates or single enantiomers, and their alkali or alkaline salts has been developed. The novel process involves the surprising discovery that protection of the free-base benzimidazole sulfoxide (e.g. omeprazole or esomeprazole), by reaction with an alkyl, aryl or aralkyl chloroformate following oxidation of the corresponding sulfide, eliminates the need for its direct isolation. Subsequent removal of the protecting group with a solution of alkali or alkaline earth alkoxide in a C1-C4 alcohol directly provides the corresponding salt. By eliminating the need to handle the free-base benzimidazole sulfoxide, this advantageous procedure provides increased chemical yields over processes described in the art. | 12-23-2010 |
20110082299 | METHOD FOR THE PREPARATION OF DABIGATRAN - A method for the manufacture of dabigatran of formula VIII, in which the product of a reaction of 4-ethylamino-3-nitrobenzoic acid chloride with ethyl-3-(pyridin-2-ylamino)propanoate, is converted to the hydrochloride using a hydrogen chloride solution producing the compound of formula III-HCl, in which the nitro group is reduced by means of a reaction with sodium dithionite, and the resulting compound of formula IV is subjected to a reaction with [(4-cyanophenyl)amino] acetic acid and oxalic acid, the product of this reaction VI-oxal is then subjected to hydrolysis and a reaction with ammonium carbonate to produce the intermediate of formula VII-HCl, which is then converted to dabigatran by means of a reaction with hexyl chloroformate. | 04-07-2011 |
20110118471 | METHOD FOR PRODUCING AN INTERMEDIATE PRODUCT OF DABIGATRAN ETEXILATE - The invention relates to a process for preparing the compound of formula 1 | 05-19-2011 |
20110224441 | METHOD FOR THE PREPARATION OF DABIGATRAN AND ITS INTERMEDIATES - Intermediates for the preparation of dabigatran of formulae (VII-2HCl) and (VII-HCl), methods for their preparation and a method for preparation of dabigatran of formula (VIII) using these intermediates. | 09-15-2011 |
20110275824 | PROCESS FOR THE MANUFACTURE OF DABIGATRAN ETEXILATE - An improved process for preparing dabigatran etexilate, as well as analogous compounds of formula 7, | 11-10-2011 |
20120116089 | BENZIMIDAZOLE DERIVATIVE - The invention relates to a process for preparing the compound of formula 1, a valuable intermediate product in the synthesis of the pharmaceutical active substance dabigatran etexilate. | 05-10-2012 |
20130116440 | PROCESS OF PREPARING A THROMBIN SPECIFIC INHIBITOR - A process of preparation of a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein R | 05-09-2013 |
20130116441 | INTERMEDIATES AND PROCESS FOR PREPARING A THROMBIN SPECIFIC INHIBITOR - Process for the preparation of a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein R | 05-09-2013 |
20130123504 | PHARMACOLOGICALLY ACTIVE COMPOUNDS CONTAINING SULFUR - Disclosed herein is a method for the production of disulfide compounds of the formula I | 05-16-2013 |
20130158270 | PROCESS FOR THE MANUFACTURE OF DABIGATRAN ETEXILATE - An improved process for preparing dabigatran etexilate, as well as analogous compounds of formula 7, | 06-20-2013 |
20140148601 | PROCESS FOR THE PREPARATION OF BENZIMIDAZOLE DERIVATIVES AND ITS SALTS - An dabigatran etexilate intermediate of Formula-6a, and the use in the preparation of dabigatran etexilate thereof. | 05-29-2014 |
20150038721 | SOLID FORMS OF DABIGATRAN ETEXILATE MESYLATE AND PROCESSES FOR THEIR PREPARATION - It relates to solid forms of dabigatran etexilate mesylate, in particular dabigatran etexilate mesylate in crystalline Form A, and in amorphous form; to processes for their preparation, and to pharmaceutical compositions comprising them. It also relates to a crystalline form of dabigatran etexilate base (Form A), and to a process for its preparation. | 02-05-2015 |
20150087842 | Process For The Preparation Of Benzimidazole Derivatives And Salts Thereof - Provided are novel salts of benzimidazole derivatives, preferably salts of benzimidazole derivatives which are useful intermediates in the synthesis of pure 1-methyl-2-[N-[4-(N-n-hexyloxycarbonylamidino)phenyl]aminomethyl]benzimidazol-5-yl-carboxylicacid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)amide and its salts. | 03-26-2015 |
20160039791 | METHOD FOR PRODUCING DABIGATRAN ETEXILATE METHANSULPHONATE - An improved method of preparing dabigatran etexilate mesylate (1-salt), | 02-11-2016 |
20160060248 | SYNTHESIS OF DABIGATRAN - The present invention relates to a process for preparation of Dabigatran etexilate or pharmaceutically acceptable salt thereof. The present invention relates to novel compounds, in particular Ethyl-3-{[(2-formyl-1-methyl-1H-benzimidazole-5-yl)carobonyl]-(2-pyridinyl)amino}propanoate and Ethyl-3-{[(2-dichloromethyl-1-methyl-1H-benzimidazole-5-yl)carbonyl]-(2-pyridinyl)amino} propanoate and process for preparation thereof. The present invention further relates to the use of these novel compounds in the preparation of Dabigatran etexilate or pharmaceutically acceptable salt thereof. | 03-03-2016 |
20190144421 | BENZIMIDAZOLE DERIVATIVES AS DUAL HISTAMINE H1 AND HISTAMINE H4 RECEPTOR LIGANDS | 05-16-2019 |
546273700 | Chalcogen bonded directly to a ring carbon of the 1,3-diazole ring | 64 |
20080214828 | PROCESS FOR PRODUCTION OF SULFOXIDE DERIVATIVES OR SALTS THEREOF IN THE AMORPHOUS STATE - Process for producing sulfoxide derivatives or salts thereof in the amorphous state, characterized by heat-drying solvated crystals of a sulfoxide derivative or a salt thereof represented by the general formula (I): | 09-04-2008 |
20080234486 | Novel Processes for the Production of Amorphous Rabeprazole Sodium - The invention is directed to overcome the problems associated with the formation of rabeprazole sodium, i.e. formation of (2-({[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methyl}sulfonyl)-1H-benzimidazole side product which is achieved by a process for the preparation of amorphous rabeprazole salt, e.g. sodium, comprising the steps of:
| 09-25-2008 |
20080234487 | SUBSTITUTED SULFOXIDE COMPOUNDS, METHODS FOR PREPARING THE SAME AND USE THEREOF - Disclosed are an optically pure compound having formula I, its pharmaceutically acceptable salt and its pharmaceutically acceptable solvate, and a use thereof in manufacturing medicaments and pharmaceutical compositions. A process for preparing the compound defined therein is also provided. | 09-25-2008 |
20080255363 | Novel Form of S-Omeprazole - The present invention relates to a novel form of the (−)-enantiomer of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole, i.e. S-omeprazole. More specifically, it relates to a novel form of the magnesium salt of the S-enantiomer of omeprazole trihydrate. The present invention also relates to processes for preparing such a form of the magnesium salt of S-omeprazole and pharmaceutical compositions containing it. Furthermore, the present invention also relates to new intermediates used in the process. | 10-16-2008 |
20080262235 | Method and Apparatus for Producing Oxidized Compound - There is provided a method and an apparatus for producing an oxidized compound, which includes measuring an electric potential of an oxidation reaction solution for producing an oxidized compound by an oxidation reaction, and determining an end point of the oxidation reaction on the basis of a predefined decrease of the electric potential, thereby simply determining the end point of the oxidation reaction to swiftly move on to the next step. For example, the apparatus for producing an oxidized compound has a reactor ( | 10-23-2008 |
20080275245 | Processes for the Preparation of Substituted Sulfoxides - The present invention relates to a process for enantioselective synthesis of substituted pyridinylmethyl sulfinyl-benzimidazole of compound of Formula (I). The process includes enantioselective catalytic oxidation of a substituted pyridinylmethyl prochiral sulfide derivative of compound of Formula (II) with an oxidizing agent in the presence of a chiral transition metal complex and a base in the absence of an organic solvent. | 11-06-2008 |
20080300411 | Process for the Preparation of the (S)-Enantiomer of Omeprazole - A process for the preparation of (S)-omeprazole from racemic omeprazole via the formation of an inclusion complex with (S)-1,1,2-triphenyl-1,2-ethanediol. (S)-Omeprazole is recovered in a substantially optically pure form either in neutral form or as a pharmaceutically acceptable salt or as its solvates including hydrates. The (S)-omeprazole 2[(S)-1,1,2-triphenyl-1,2-ethanediol] inclusion complex is new. This resolution process proceeds with high yields and high optical purity. | 12-04-2008 |
20080312449 | New Compounds - The novel optically pure compounds Na | 12-18-2008 |
20090005570 | Method for preparing 2- (2-pyridinylmethylsulfinyl) benzimidazoles - The present invention provides a method for preparing an antiulcer agent, 2-(2-pyridinylmethylsulfinyl)benzimidazoles, such as Omeprazole, Lansoprazole, Pantoprazole and Rabeprazole, which includes oxidizing an intermediate having a linkage of methylthio group (—CH | 01-01-2009 |
20090018339 | Process For Preparing Crystalline Form A Of Lansoprazole - The present invention relates to a process for preparing Crystalline Form A of Lansoprazole. Specifically, the present invention relates to a process for preparing highly pure Crystalline Form A of Lansoprazole in a large scale without any additional conversion step, even by using ethanol in which Crystalline Form B is easily formed. | 01-15-2009 |
20090076277 | Process for the preparation of pyridine-methylsulfinyl compounds - A process for the preparation of a compound of formula (I), or a salt thereof, | 03-19-2009 |
20090082572 | PROCESS FOR AMORPHOUS ESOMEPRAZOLE - The present invention relates to a commercially viable process for preparation of amorphous esomeprazole. Thus, amorphous esomeprazole is prepared by suspending esomeprazole in water and then subjecting the suspension to lyophilization at −70° C. | 03-26-2009 |
20090124811 | Method for resolving omeprazole salts - The present invention relates to the resolution by preferential crystallization of potassium salts of racemic omeprazole which is a solvate of ethanol and/or of ethylene glycol, which consists in converting the omeprazole to the potassium salt in the form of a solvate or of a mixture of these solvates in the presence of an excess of inorganic base which is a source of potassium, the said potassium salts existing in the form of conglomerates, and in then resolving the said conglomerates, independently or simultaneously, by preferential crystallization in order to separate the two (S) and (R) enantiomers of these potassium salts of omeprazole. | 05-14-2009 |
20090182149 | SALT OF SULFINYLBENZIMIDAZOLE COMPOUND, AND CRYSTAL AND AMORPHOUS FORM THEREOF - Salts of 2-[({4-[(2,2-dimethyl-1,3-dioxan-5-yl)methoxy]-3,5-dimethylpyridin-2-yl}methyl)sulfinyl]-1H-benzimidazole and their crystalline and amorphous forms. | 07-16-2009 |
20090198066 | AMORPHOUS ESOMEPRAZOLE HYDRATE - The present invention relates to a novel amorphous form of esomeprazole hydrate, to a process for its preparation and to a pharmaceutical composition containing it. Thus, tetrahydrofuran and water are added to esomeprazole potassium salt at 25-30° C., cooled to 20° C. and then the pH is adjusted to 7.5-8.0 with acetic acid. The reaction mass is cooled to 5° C., stirred for 2 to 3 hours at 0-5° C., filtered the mass, washed with chilled mixture of water and tetrahydrofuran (2:1) and again washed with water. The wet cake is dried at 30-35° C. under vacuum to reach the moisture content to 25-30%. The solid is again dried in rotovapour at 25-30° C. under nitrogen atmosphere to give amorphous esomeprazole hydrate. | 08-06-2009 |
20090253911 | New Compounds Useful for the Synthesis of S- and R-Omeprazole and a Process for Their Preparation - The present invention relates to an improved method for the synthesis of the (S)- or (R)-enantiomer of omeprazole, characterized in that 2-[[(4-X-3,5-dimethylpyridin-2-yl)methyl]thio]-5-methoxy-1H-benzimidazole or 2-[[(4-X-3,5-dimethyl-1-oxidopyridin-2-yl)methyl]thio]-5-methoxy-1H-benzimidazole, wherein X is a leaving group, is oxidized into the corresponding sulphoxide which is obtained as a crystalline compound. Recrystallisation of the thus obtained sulphoxide results in a compound of enhanced chemical and optical purity, which is subsequently transformed into the (S)- or (R)-enantiomer of omeprazole. | 10-08-2009 |
20090259047 | BARIUM SALT OF BENZIMIDAZOLE DERIVATIVE - The invention relates to crystalline barium salt of (S)-omeprazole, which is (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole. The invention also relates to processes for preparing crystalline barium salt of (S)-omeprazole and pharmaceutical compositions that include the crystalline barium salt of (S)-omeprazole so prepared. | 10-15-2009 |
20090264658 | SALTS OF BENZIMIDAZOLE DERIVATIVE WITH AMINES AND PROCESS FOR MANUFACTURING THE SAME - It is an object of the present invention to provide (1) a process for manufacturing alkali metal salts of 2-[{4-(3-methoxypropoxy)-3-methylpyridin-2-yl}methylsulfinyl]-1H-benzimidazole which are useful as gastric acid secretion inhibitors, anti-ulcer agents and other drugs and (2) salts of 2-[{4-(3-methoxypropoxy)-3-methylpyridin-2-yl}methylsulfinyl]-1H-benzimidazole with amines which are intermediates for the production of the alkali metal salts, and a process for manufacturing the same. According to the present invention, disclosed are salts represented by the following formula (I): | 10-22-2009 |
20090306393 | PROCESS FOR PREPARING OF, IMPURITIES FREE, SUBSTITUTED 2-BENZIMIDAZOLE-SULFOXIDE COMPOUND - The present invention relates to an improved process for the preparation of pantoprazole free from overoxidation impurities. The process enables better control of the process and therefore the quality of the products obtained, avoiding the formation of impurities. | 12-10-2009 |
20100010230 | Method for the purification of lansoprazole - The present invention relates to an improved process for the preparation of Lansoprazole of formula (I). More particularly, the present invention relates to a method for the purification of crude Lansoprazole in a solvent in presence of an alkali salt of an organic acid or in presence of an organic base such as piperidine or imidazole. | 01-14-2010 |
20100016605 | Process - A one-pot process for the preparation of pantoprazole sodium by reacting 2-chloro methyl 3,4-dimethoxy pyridine hydrochloride with 2-mercapto-5-difluoromethoxy benzimidazole in an organic solvent system in presence of a phase transfer catalyst and further treating with aqueous sodium hypohalite solution comprising sodium hydroxide to obtain pantoprazole sodium in high yield and purity. The process for conversion of pantoprazole sodium to pantoprazole sodium sesquihydrate and also pantoprazole sodium monohydrate are also disclosed herein. | 01-21-2010 |
20100016606 | PREPARATION OF AMORPHOUS HYDROUS ESOMEPRAZOLE MAGNESIUM - A hydrate of esomeprazole magnesium in the form of an amorphous solid is provided. Methods of preparation and use of, as well as formulation containing the hydrate of esomeprazole magnesium in the form of an amorphous solid are also provided. | 01-21-2010 |
20100022778 | PROCESS FOR PRODUCTION OF SULFINYLBENZIMIDAZOLE COMPOUNDS OR SALTS THEREOF - It is an object of the present invention to provide a process for the production on an industrial scale of a compound (1) or a salt thereof. There is provided a process for the production of compound (1) represented by the formula or a salt thereof: (wherein R1 and R3 independently represents a hydrogen atom or a methyl group), the process comprising the steps of: (a) reacting together a compound (3T) represented by the formula: (wherein X1 represents a leaving group, and R1 and R3 are defined as above) and (2,2-dimethyl-1,3-dioxan-5-yl)methanol represented by the formula or a salt thereof: so as to produce a compound (2T) represented by the formula (wherein R1 and R3 are defined as above); and (b) reacting the compound represented by above formula (2T) with an oxidizing agent. | 01-28-2010 |
20100022779 | Isotopically substituted proton pump inhibitors - The invention relates to compounds of formula 1 | 01-28-2010 |
20100087652 | S-Omeprazole Magnesium - The present invention discloses a process for preparing a magnesium salt of S-omeprazole. The S-omeprazole salt preferably has a water content below about 4.8% by weight, a magnesium content of about 3.4-4.0% by weight, calculated on the weight of anhydrous, solvent free S-omeprazole magnesium, and has an optical purity of at least about 85% entantiomeric excess (“e.e.”). In addition, the present invention provides a magnesium salt of S-omeprazole which is substantially free of neutral omeprazole, meaning that the product contains less than about 3% by weight of a sum of neutral S-omeprazole and neutral omeprazole. Moreover, the S-omeprazole magnesium according to the invention preferably has assay of related substances and degradation products of less than about 0.1% by weight as determined by high performance liquid chromatography (HPLC). | 04-08-2010 |
20100125142 | PROCESS FOR PREPARING AN OPTICALLY ACTIVE PROTON PUMP INHIBITOR - An improved process for the preparation of (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole of Formula I, (I) with high enantiomeric excess from racemic mixture. | 05-20-2010 |
20100125143 | PROCESS FOR THE PREPARATION OF DEXLANSOPRAZOLE - Process for the preparation of (R)-2-[[[3-methyl-4(2,2,2-trifluoroethoxy)-2-piridyl]methyl]sulfinyl]benzimidazole (Dexlansoprazole) and new intermediates useful in its preparation. | 05-20-2010 |
20100137607 | BARIUM SALT OF BENZIMIDAZOLE DERIVATIVE - The invention relates to crystalline barium salt of (S)-omeprazole, which is (S)- | 06-03-2010 |
20100145058 | BARIUM SALT OF BENZIMIDAZOLE DERIVATIVE - The invention relates to crystalline barium salt of (S)-omeprazole, which is (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole. The invention also relates to processes for preparing crystalline barium salt of (S)-omeprazole and pharmaceutical compositions that include the crystalline barium salt of (S)-omeprazole so prepared. | 06-10-2010 |
20100160639 | PROCESS FOR THE PREPARATION OF OPTICALLY PURE OR OPTICALLY ENRICHED ENANTIOMERS OF SULPHOXIDE COMPOUNDS - A process for preparation of optically pure or optically enriched enantiomers of sulphoxide compounds of formula (I), such as omeprazole and structurally related compounds, as well as their salts and hydrates. The said process comprises
| 06-24-2010 |
20100174087 | PROCESS FOR PREPARATION OF ENANTIOMERICALLY PURE ESOMEPRAZOLE - The present invention provides an improved and commercially viable process for preparation of substantially enantiomerically pure esomeprazole in neutral form or as a pharmaceutically acceptable salt or as its solvates including hydrates. Thus, for example, a compound containing a mixture of 1-(S)-camphorsulfonyl-5-methoxy-2-[(3,5-dimethyl-4-methoxy-2-pyridyl)methyl-(S)-sulfinyl]-1H-benzimidazole and 1-(S)-camphorsulfonyl-6-methoxy-2-[(3,5-dimethyl-4-methoxy-2-pyridyl)methyl-(S)-sulfinyl]-1H-benzimidazole is hydrolyzed with barium hydroxide, isolated the resulting esomeprazole barium salt followed by neutralization with an acid to yield substantially enantiomerically pure esomeprazole in neutral form and then converted into its pharmaceutically acceptable salts. | 07-08-2010 |
20100179328 | PROCESS FOR PRODUCING SULPHOXIDE COMPOUNDS - Disclosed herein, a process for producing sulphoxide compound of the Formula (I) by asymmetrically oxidizing a prochiral sulphide of the Formula (II) with an effective amount of oxidizing agent in the presence of a chiral transition metal complex without using an organic solvent and base. | 07-15-2010 |
20100190989 | PROCESS FOR THE PREPARATION OF PURE RABEPRAZOLE - The present invention relates to a process for the preparation of pure Rabeprazole sulfoxide using the solvent mixture for the extraction steps and this invention further relates to the process for the preparation of amorphous Rabeprazole sodium using pure rabeprazole base in presence of aqueous NaOH and water miscible solvent and adding an anti-solvent. | 07-29-2010 |
20100204478 | IMPROVED PROCESS FOR AMOPHOUS RABEPRAZOLE SODIUM - The present invention provides an improved and efficient process for the preparation of highly pure amorphous rabeprazole sodium. Thus, for example, rabeprazole is dissolved in an alcoholic sodium hydroxide solution followed by carbon treatment, the resulting filtrate is distilled under vacuum at 50-52° C. followed by co-distillation with cyclohexane and the resulting residue is dissolved in anisole; the solution is added to cyclohexane under agitation and then the precipitated solid collected by filtration or centrifugation. | 08-12-2010 |
20100204479 | CRYSTALLINE FORMS OF DEXLANSOPRAZOLE - The present invention relates to novel crystalline forms of Dexlansoprazole and a process for the preparation of amorphous Dexlansoprazole. | 08-12-2010 |
20100210846 | Process for preparing 2-(2-pyridylmethyl)-sulfinyl-1H-benzimidazoles and the intermediate compounds used therein - The present invention relates to a process for preparing 2-(2-pyridylmethyl)sulphinyl-1H-benzimidazoles that are proton pump inhibitors, using as intermediates 2-benzimidazolyl-sulphinic acid derivatives. The present invention also relates to the intermediate compounds, their use and a process for the preparation thereof. These novel intermediate compounds are 2-benzimidazolylsulphinicacid esters that are obtained from their corresponding alkaline salts, which are in turn obtained by oxidation of substituted 2-mercaptobenzimidazoles. The intermediate compounds of the invention are converted into 2-(2-pyridylmethyl)sulphinyl-1H-benzimidazoles by reaction with substituted 2-methylpyridines. | 08-19-2010 |
20100210847 | PROCESS FOR THE PREPARATION OF PANTOPRAZOLE SODIUM AND PANTOPRAZOLE SODIUM SESQUIHYDRATE - The present invention relates to a process for the preparation of pantoprazol sodium sesquihydrate of formula (I) and pantoprazole sodium. | 08-19-2010 |
20100222591 | New Compounds - The novel optically pure compounds Na | 09-02-2010 |
20100267959 | PROCESS FOR THE PREPARATION OF ESOMEPRAZOLE MAGNESIUM DIHYDRATE - The present invention relates to a process for the preparation of esomeprazole magnesium dihydrate, specifically, esomeprazole magnesium crystalline dihydrate form A; and pharmaceutical compositions thereof. | 10-21-2010 |
20100286400 | CRYSTALLINE SOLVATED FORMS OF (R)-2-[[[3-METHYL-4-(2,2,2-TRIFLUOROETHOXY)-2-PYRIDINYL]METHYL]SULFINYL]-- 1H-BENZIMIDAZOLE - The novel hydrate, methanol solvate, ethanol solvate, ethanol•hydrate and isopropanol•hydrate crystals of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole of the present invention are useful as excellent antiulcer agents. | 11-11-2010 |
20110028728 | PROCESS FOR THE PREPARATION OF CRYSTALLINE DEXLANSOPRAZOLE - Process for the preparation of crystalline anhydrous (R)-2-[[[3-methyl-4-(2,2,2-trifluoroetoxy)-2-piridyl]methyl]sulphinyl]benzimidazole (dexlansoprazole). | 02-03-2011 |
20110046383 | CRYSTALLINE S-OMEPRAZOLE STRONTIUM HYDRATE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME - Disclosed are a crystalline S-omeprazole strontium hydrate for the prevention or treatment of gastric acid-related diseases, which has high optical purity, theremostability, solubility and nonhygroscopicity, a method for preparing same, and a pharmaceutical composition containing same. | 02-24-2011 |
20110130570 | Novel Form of S-Omeprazole - The present invention relates to a novel form of the (−)-enantiomer of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2 -pyridinyl)-methyl]sulfinyl]-1 | 06-02-2011 |
20110184182 | COMPOUNDS FOR PRODUCING SUBSTITUTED SULFOXIDES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF - Disclosed herein are novel compounds which are useful as intermediates for producing substituted sulfoxide compounds and a process for producing the same. Further disclosed is a process for producing the substituted sulfoxide compounds used as pharmacologically active agents, employing the novel intermediates of the present invention. | 07-28-2011 |
20110213155 | OPTICAL PURIFICATION OF ESOMEPRAZOLE - The present invention relates to process for optical purification of esomeprazole or a salt thereof. Thus, esomeprazole sodium having 20 to 1% R-omeprazole by weight of the sum of the contents of esomeprazole and R-omeprazole is precipitated from a solvent selected from an alcohol or a mixture of alcohols and the precipitated solid is collected to obtain optically pure esomeprazole sodium. | 09-01-2011 |
20110257405 | PROCESS FOR PRODUCING CRYSTAL - The present invention relates to a production method of a crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]benzimidazole.n′H | 10-20-2011 |
20120197021 | OPTICAL RESOLUTION OF SUBSTITUTED 2-(2-PYRIDINYLMETHYLSULPHINYL)-1H-BENZIMIDAZOLES - The present invention relates to process for preparation of optical resolution of substituted 2-(2-pyridinylmethylsulphinyl)-1H-benzimidazoles either as a single enantiomer or in an enantiomerically enriched form. Thus, for example, R-1,1′-binaphtyl-2-2′-diyl hydrogen phosphate was reacted with 2-[[[3-methyl-4-(2,2,2-trifluoro-ethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole (Lansoprazole) in a mixture of benzene and cyclohexane to obtain diasteremeric complexes. The diasteremeric complexes were subjected to fractional crystallization to obtain R-2-[[[3-methyl-4-(2,2,2-trifluoro-ethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole.R-1,1′-binaphthyl-2-2′-diyl hydrogen phosphate. The separated isomer was treated with sodium bicarbonate in a mixture of ethyl acetate and water to obtain R-2-[[[3-methyl-4-(2,2,2-trifluoro-ethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole (dexlansoprazole). | 08-02-2012 |
20120215003 | PROCESS FOR THE RESOLUTION OF OMEPRAZOLE - The present invention relates to process for the resolution of omeprazole. The present invention further provides a novel compound of enantiomers of omeprazole cyclic amine salt and a process for preparing it. The present invention also provides a solid of (R)- or (S)-omeprazole cyclic amine salt and a process for preparing it. The present invention also provides a process for the preparation of esomeprazole magnesium dihydrate substantially free of its trihydrate form. The present invention also provides a process for the preparation of recovery of chiral BINOL. | 08-23-2012 |
20120309976 | PREPARATION PROCESS OF THE SODIUM SALT OF ESOMEPRAZOLE - A preparation process of esomeprazole sodium substantially free of sulfone impurity including the steps of: a) combining either esomeprazole with a (C | 12-06-2012 |
20120316344 | BENZIMIDAZOLE COMPOUND CRYSTAL - A novel crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole or a salt thereof of the present invention is useful for an excellent antiulcer agent. | 12-13-2012 |
20130012714 | NOVEL SOLVATE OF DEXLANSOPRAZOLE - The present invention provides novel solvate of dexlansoprazole (or R-lansoprazole), particularly diol solvate and its hydrate form of dexlansoprazole (or R-lansoprazole) which is chemically known as (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole compound of the formula (I), as well as processes for the preparation thereof. The said solvates are useful in the preparation of dexlansoprazole with enhanced chiral purity and better HPLC purity with less sulphone impurity content. | 01-10-2013 |
20130030186 | PROCESS FOR PREPARING SULPHOXIDE COMPOUNDS - A process for the enantioselective synthesis of a sulphoxide of a compound of Formula I or a pharmaceutically acceptable salt thereof in the form of a single enantiomer or in an enantiomerically enriched form | 01-31-2013 |
20130150588 | Salts and Polymorphs of Dexrabeprazole - The present invention provides dexrabeprazole magnesium hydrate and a process for its preparation. The present invention also provides a magnesium, calcium or potassium salt of dexrabeprazole, optionally in amorphous form, and processes for its preparation. | 06-13-2013 |
20130197232 | PROCESS FOR THE PREPARATION OF CRYSTALLINE FORMS OF DEXLANSOPRAZOLE - The present invention relates to crystalline forms of dexlansoprazole designated as forms A and B, and their preparation. The present invention further relates to processes for the preparation of anhydrous dexlansoprazole and dexlansoprazole sesquihydrate using crystalline Forms A and B of dexlansoprazole. | 08-01-2013 |
20130197233 | SALTS OF DEXLANSOPRAZOLE AND THEIR PREPARATION - The present invention relates to the salts of dexlansoprazole in amorphous form. The present invention further relates to processes for the preparation of salts of dexlansoprazole. | 08-01-2013 |
20130204002 | PROCESS FOR THE PREPARATION OF DEXLANSOPRAZOLE - The present invention relates to a process for the preparation of crystalline dexlansoprazole. | 08-08-2013 |
20130231486 | COMPOUNDS FOR PRODUCING SUBSTITUTED SULFOXIDES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF - Disclosed herein are novel compounds which are useful as intermediates for producing substituted sulfoxide compounds and a process for producing the same. Further disclosed is a process for producing the substituted sulfoxide compounds used as pharmacologically active agents, employing the novel intermediates of the present invention. | 09-05-2013 |
20130281704 | SALTS OF BENZIMIDAZOLE COMPOUND AND USE THEREOF - A sodium salt, magnesium salt, lithium salt, potassium salt, calcium salt or barium salt of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole, and a pharmaceutical composition comprising the salt. The novel salt is useful as an excellent antiulcer agent. | 10-24-2013 |
20130303772 | CRYSTALLINE S-OMEPRAZOLE STRONTIUM HYDRATE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME - Disclosed are a crystalline S-omeprazole strontium hydrate for the prevention or treatment of gastric acid-related diseases, which has high optical purity, thermostability, solubility and nonhygroscopicity, a method for preparing same, and a pharmaceutical composition containing same. | 11-14-2013 |
20140012006 | BENZIMIDAZOLE COMPOUND CRYSTAL - A novel crystal of (R)- | 01-09-2014 |
20140100370 | METHOD AND APPARATUS FOR PRODUCING OXIDIZED COMPOUND - A method of producing an oxidized compound is disclosed. An electric potential is measured of an oxidation reaction solution for producing an oxidized compound by an oxidation reaction, and an end point is determined of the oxidation reaction on the basis of a predefined decrease of the electric potential. Preferably, after the electric potential of the oxidation reaction solution is reached to a highest electric potential, a point is determined where the amount of an electric potential dropped from the highest electric potential reaches the predefined amount of an electric potential as the end point of the oxidation reaction. The method also may introduce an oxidation reaction terminating agent to the oxidation reaction solution immediately after determining the end point of the oxidation reaction. | 04-10-2014 |
20140275550 | LANSOPRAZOLE COMPOUND AND NOVEL PREPARATION METHOD THEREOF - A process for purifying lansoprazole comprises 1) loading crude lansoprazole material onto a macroporous resin column; 2) concentrating the eluate from the column in a crystallization vessel by vacuum; 3) seeding lansoprazole crystal; 4) crystallizing the lansoprazole; 5) separating the precipitated crystals. The process especially has large processing capacity, can be carried out continuously and therefore suitable for industrial production, improving the quality of formulated products and reducing side effects. | 09-18-2014 |
20140357870 | PROCESS FOR THE PREPARATION OF DEXLANSOPRAZOLE - The present invention relates to a process for the preparation of dexlansoprazole.xH | 12-04-2014 |
20150080579 | Salts and Polymorphs of Dexrabeprazole - The present invention provides dexrabeprazole magnesium hydrate and a process for its preparation. The present invention also provides a magnesium, calcium or potassium salt of dexrabeprazole, optionally in amorphous form, and processes for its preparation. | 03-19-2015 |